Возможности модифицирующего влияниямакролидных антибиотиков на течение острыхреспираторных заболеваний, вызванных вирусамигриппа и риновирусами (обзор)
Возможности модифицирующего влияниямакролидных антибиотиков на течение острыхреспираторных заболеваний, вызванных вирусамигриппа и риновирусами (обзор)
1. Jang YJ, Kwon HJ, Lee BJ. Effect of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J 27: 12–9.
2. Abisheganaden JA, Avila PC, Kishiyaa JL et al. Effects of clarithromycin on experimental rhinovirus-16 colds: a randomized, double blind controlled trial. Am J Med 2000; 108: 453–9.
3. Wallwark B, Coman W, Mackay-Sim A, Cervin A. Effect of clarithromycin on NF-kB and transforming growth factor-beta in chronic rhinosinusitis. Laryngoscope 2004; 114: 286–90.
4. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal epithelial cells simultaneously. Laryngoscope 2009; 119: 1406–11.
5. Wang JH, Lee SH, Kwon HJ, Jang YJJ. Clarithromycin inhibits rhinovirus-induced bacterial adhesions to nasal epithelial cells. Laryngoscope 2010; 120.
6. Miyamoto D, Hasegawa S, Sriwilaijaroen N et al. Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull 2008; 31 (2): 217–22.
7. Yamaya M, Shinya K, Hatachi Y et al. Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells?